Milan, Italy (June 22, 2023)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its granting of the patent No. 2020-514215 in Japan by the Japanese Patent Office.

The patent application No. 2020-514215 is referred to the first family of patents, already granted in Italy and Europe. The granting of this patent represents a fundamental milestone for the company and strengthens one of the main corporate assets in order to promote and develop innovative drug-delivery technology in the field of ophthalmology.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.